REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Tobacco firm Philip Morris seals deal for UK's Vectura with 75% support

Thu, 16th Sep 2021 07:33

* Holders of roughly 75% Vectura shares tender support

* PMI needed 50% backing for deal to go through

* Extends deadline for other holders to tender shares by
Sept. 30
(Adds detail, background)

By Pushkala Aripaka

Sept 16 (Reuters) - Cigarette maker Philip Morris (PMI)
has clinched the roughly 1-billion-pound takeover of
inhaler maker Vectura after winning the backing of about
75% of shareholders in the British company, part of its
expansion beyond tobacco.

Vectura shareholders had until Sept. 15 to decide whether to
support the 165 pence-per-share bid from PMI, which sought to
buy the London-listed asthma drug maker as part of its plan to
go "smoke-free" and switch to healthcare and wellness products.

"We have reached an important milestone in our acquisition
of Vectura and are pleased to have secured over 74% of the
company's shares, in excess of the 50% required to make our
offer unconditional and PMI the majority shareholder," PMI Chief
Executive Jacek Olczak said in a statement on Thursday.

PMI had received the shares from shareholders through a
public tender offer process, and the cigarette maker's offer for
Vectura cannot be withdrawn now.

PMI, which fought off private equity firm Carlyle Group
for the buyout of Vectura, had switched its proposal to a
takeover offer from a so-called scheme of arrangement to raise
its chances.

The switch allowed PMI to require the support of holders of
just over 50% of Vectura shares for the deal to go through.

Philip Morris has received regulatory clearances for the
deal and had won the backing of Vectura's board, but health
groups are questioning the idea of a tobacco company making
money from treating the very illnesses that cigarettes cause.

Olczak said PMI would provide Vectura's scientists with the
resources and expertise to reach a target of at least $1 billion
in net revenue from its "Beyond Nicotine" products by 2025.

The U.S.-based company has also extended the deadline for
the remaining Vectura shareholders to tender their shares to
Sept. 30.

($1 = 0.7234 pounds)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Devika
Syamnath and Emelia Sithole-Matarise)

More News
19 Mar 2021 09:46

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

BROKER RATINGS: Barclays and Goldman Sachs downgrade Hammerson

Read more
18 Mar 2021 10:36

Vectura shares rise on swing to profit, GBP115 million special payout

Vectura shares rise on swing to profit, GBP115 million special payout

Read more
18 Mar 2021 07:43

Royalty income, litigation win see Vectura beat expectations

(Sharecast News) - Vectura reported a 6.9% improvement in its total revenue on Thursday, to £190.6m, driven by development services and a surge in income from royalties.

Read more
11 Mar 2021 16:13

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
5 Mar 2021 12:29

Vectura delays results because of KPMG staff shortage

(Sharecast News) - Vectura delayed the publication of its annual results after KPMG asked for more time to audit the accounts because of a staff shortage caused by Covid-19.

Read more
2 Mar 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
22 Jan 2021 09:32

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

LONDON BROKER RATINGS SUMMARY: Deutsche Bank Ups British Land, Landsec

Read more
12 Jan 2021 10:13

Vectura Forecasts 2020 Earnings To Top Board Expectations

Vectura Forecasts 2020 Earnings To Top Board Expectations

Read more
12 Jan 2021 08:16

Vectura reports 'strong' operational performance in 2020

(Sharecast News) - Inhaled medicines-focussed pharmaceutical company Vectura Group updated the market on its trading on Tuesday, saying it expected revenue and adjusted EBITDA for 2020 to be ahead of board expectations, following the fourth quarter approval of VR315 (US), or generic 'Advair', alongside Hikma.

Read more
30 Dec 2020 19:10

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

UK EXECUTIVE CHANGE SUMMARY: Nutrition Firm Director Joins Tate & Lyle

Read more
29 Dec 2020 12:04

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation

Read more
29 Dec 2020 10:04

Glaxo not seeking re-hearing in Ellipta litigation, says Vectura

(Sharecast News) - Vectura said on Tuesday that GlaxoSmithKline has not sought to petition the US Court of Appeals for a re-hearing in the companies' ongoing litigation over GSK's Ellipta inhalers.

Read more
18 Dec 2020 17:08

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

LONDON MARKET CLOSE: Stocks Fall As Investors Sweat On Brexit Deal

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 10:45

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

UK WINNERS & LOSERS SUMMARY: US Generic Advair Ok Lifts Hikma, Vectura

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.